Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

completed250%
unknown125%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
withdrawnphase_2

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

NCT01892644
unknown

Assay Development for Cancer Biomarkers

NCT02874729
completedphase_2

Cytochrome P450 2E1 and Iron Overload

NCT00138684
completednot_applicable

Study of the Effects of Iron Levels on the Lungs at High Altitude

NCT00952302

Clinical Trials (4)

Showing 4 of 4 trials
NCT01892644Phase 2

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Withdrawn
NCT02874729

Assay Development for Cancer Biomarkers

Unknown
NCT00138684Phase 2

Cytochrome P450 2E1 and Iron Overload

Completed
NCT00952302Not Applicable

Study of the Effects of Iron Levels on the Lungs at High Altitude

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4